Business Organization (Details) $ / shares in Units, $ in Millions |
9 Months Ended | ||
|---|---|---|---|
|
Aug. 01, 2026
USD ($)
$ / shares
shares
|
Sep. 30, 2026
product
$ / shares
|
Dec. 31, 2025
$ / shares
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Number of commercial products | product | 9 | ||
| Common stock, par value (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 |
| Invidior Pharmaceuticals, Inc. | Acquisition Term Loan | Unsecured Debt | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Commitments to extend credit | $ 650 | ||
| Supernus Pharmaceuticals, Inc. | Invidior Pharmaceuticals, Inc. | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Business combination, share exchange ratio | shares | 1.5401 | ||
| One-time special cash dividend | $ 1,000 |